Zhejiang Zhenyuan Share Co Ltd

Zhejiang Zhenyuan maintains a conservative capital structure with a debt-to-equity ratio of 0.11, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 2.13, suggesting it can cover its short-term obligations but with limited excess capacity. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.

Profitability metrics for Zhejiang Zhenyuan are modest, with a return on equity (ROE) of 1.23% and a return on assets (ROA) of 0.78%. These figures are below the typical thresholds for pharmaceutical firms, which often aim for ROE above 10% and ROA above 5%. The company's operating margin is 2.92% (calculated as operating income of 26.65 million CNY on revenue of 914.19 million CNY), which is significantly lower than the industry median of 12.5%.

The company's revenue is concentrated in a single geographic market, China, with no disclosed international operations. This concentration increases exposure to domestic regulatory and economic shifts. Segment-wise, Zhejiang Zhenyuan does not report detailed business segments, but its primary revenue stream is from pharmaceutical product sales.

Zhejiang Zhenyuan's growth trajectory is flat, with no significant revenue growth reported in the latest financial period. The company's capital expenditures are negative at -127.62 million CNY, indicating asset disposals or a reduction in investment in physical infrastructure. This suggests a potential shift in strategy or a focus on cost optimization rather than expansion.

The company's risk profile is moderate, with a low dilution risk due to no additional shares outstanding beyond the basic shares. However, the negative net cash position and the absence of a clear growth strategy raise concerns about long-term sustainability. The company has not disclosed any recent equity offerings or dilutive events, but the negative cash flow from operations could necessitate future financing.

Recent filings and transcripts do not indicate any major strategic shifts or new product launches. The company's 10-K filing highlights ongoing challenges in the domestic pharmaceutical market, including pricing pressures and regulatory scrutiny. No material events have been disclosed in the latest quarter that would significantly alter the company's trajectory.

Zhejiang Zhenyuan Co Ltd (000705.SZ) has been formally classified within the Healthcare economic sector, with its primary activity identified as Pharmaceuticals & Medical Research. This taxonomic update provides a clearer definition of the company’s operational focus, establishing a baseline for sector-specific analysis and peer comparison. In terms of risk profile, the company now carries a "low" dilution risk assessment. This indicates that the likelihood of significant share count expansion or equity dilution is currently considered minimal, offering a degree of stability for existing shareholders regarding their ownership percentage. Conversely, the liquidity risk assessment has been set at "medium." This suggests that while the stock is not facing immediate liquidity crises, there may be moderate constraints on trading volume or ease of execution, which investors should monitor when planning entry or exit strategies. The company currently operates with a lean governance structure, featuring only one listed officer. Additionally, there is a notable absence of analyst coverage, index membership, and disclosed top holders, highlighting a lack of institutional visibility and professional research attention surrounding the stock. [doc:000705.sz-ha-financials]

The company maintains a low debt-to-equity ratio of 0.11, indicating conservative leverage compared to the pharmaceutical cohort median of 0.18.

Cash conversion metrics rank best-in-class at 5.62, significantly outperforming the pharmaceutical cohort median of 0.95.

Dilution risk is assessed as low, suggesting limited immediate threat to existing shareholder equity value from share issuance.

The company faces high credit risk, indicating significant concerns regarding its ability to meet financial obligations.

Revenue ¥751.7M; Operating income ¥41.2M.

• ▍Revenue ¥751.7M
• ▍Operating income ¥41.2M
• ▍Net margin 4.8%

Revenue ¥889.1M; Operating income -¥2.5M.

• ▍Revenue ¥889.1M
• ▍Operating income -¥2.5M
• ▍Net margin -1.0%

Revenue ¥3.74B, −8,9% YoY; Operating income −50,8% YoY.

• ▍Revenue ¥3.74B, −8,9% YoY
• ▍Operating income −50,8% YoY
• ▍Net income −57,5% YoY
• ▍Free cash flow −682,1% YoY
• ▍Net margin 0.9%

Revenue ¥4.11B, −0,9% YoY; Operating income +7,5% YoY.

• ▍Revenue ¥4.11B, −0,9% YoY
• ▍Operating income +7,5% YoY
• ▍Net income +4,8% YoY
• ▍Free cash flow −512,7% YoY
• ▍Net margin 2.0%